Buchumschlag

Vacuum-assisted breast biopsy after neoadjuvant systemic treatment for reliable exclusion of residual cancer in breast cancer patients

About 40 % of women with breast cancer achieve a pathologic complete response in the breast after neoadjuvant systemic treatment (NST). To identify these women, vacuum-assisted biopsy (VAB) was evaluated to facilitate risk-adaptive surgery. In confirmatory trials, the rates of missed residual cancer...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kölbel, Vivian (VerfasserIn) , Pfob, André (VerfasserIn) , Schäfgen, Benedikt (VerfasserIn) , Sinn, Peter (VerfasserIn) , Feißt, Manuel (VerfasserIn) , Golatta, Michael (VerfasserIn) , Gomez, Christina (VerfasserIn) , Stieber, Anne (VerfasserIn) , Bach, Paul (VerfasserIn) , Rauch, Geraldine (VerfasserIn) , Heil, Jörg (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2022
In: Annals of surgical oncology
Year: 2022, Jahrgang: 29, Heft: 2, Pages: 1076-1084
ISSN:1534-4681
DOI:10.1245/s10434-021-10847-9
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1245/s10434-021-10847-9
Volltext
Verfasserangaben:Vivian Koelbel, André Pfob, Benedikt Schaefgen, Peter Sinn, Manuel Feisst, Michael Golatta, Christina Gomez, Anne Stieber, Paul Bach, Geraldine Rauch, Joerg Heil
Beschreibung
Zusammenfassung:About 40 % of women with breast cancer achieve a pathologic complete response in the breast after neoadjuvant systemic treatment (NST). To identify these women, vacuum-assisted biopsy (VAB) was evaluated to facilitate risk-adaptive surgery. In confirmatory trials, the rates of missed residual cancer [false-negative rates (FNRs)] were unacceptably high (> 10%). This analysis aimed to improve the ability of VAB to exclude residual cancer in the breast reliably by identifying key characteristics of false-negative cases.
Beschreibung:Gesehen am 08.08.2023
Beschreibung:Online Resource
ISSN:1534-4681
DOI:10.1245/s10434-021-10847-9

Ähnliche Einträge